IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Human Journals
Review Article
February 2023 Vol.:26, Issue:3

Pharmacovigilance: A Master Key for Drug Safety

IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Kagitham Geethanjali*, J. Praveen Kumar

Krishna Teja Pharmacy College, Renigunta road, Tirupati, Tirupati district, Andhra Pradesh, India 517520.

Submitted: 20 January 2023
Accepted: 27 January 2023
Published: 28 February 2023

HUMAN JOURNALS
www.ijppr.humanjournals.com

Keywords: Pharmacovigilance, Adverse drug reactions, Drug Safety, Drug regulation systems, Risk management plans

ABSTRACT

Drug use can be made safe and effective with the help of pharmacovigilance. Spontaneous reporting is used to record adverse drug reactions, a common problem in underdeveloped nations. To protect the security of medicines and prevent ADRs, pharmacovigilance employs a variety of risk management strategies. Pharmacovigilance is a crucial component of clinical research and plays a significant role in it. A nation must have a pharmacovigilance system in place to safeguard its citizens from any possible danger that new pharmaceuticals may bring with them. Globally, pharmacovigilance is very prevalent. Effective drug regulating systems, clinical practice, and public health initiatives all depend on it. An independent system of evaluation would be used to develop the current global network of pharmacovigilance centers, organized by the Uppsala Monitoring Centre. This would consider debatable and crucial medication safety issues that have the potential to adversely affect public health across international borders. Pharmacovigilance has recently been used sparingly, mostly to identify adverse medication reactions that were previously either undetected or poorly understood.

INTRODUCTION

The manner that diseases are treated has changed because of drugs. Adverse responses are a known risk of medication therapy, despite all the benefits of pharmacotherapy. A prevalent and frequently avoidable cause of disease, disability, and death is an adverse drug response (ADR). "An appreciably damaging or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which predicts hazards from future administration and warrants prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the product," is how an ADR is defined.

Pharmacovigilance is described by The World Health Organization (WHO) as the science and practices of the detection, assessment, understanding, and prevention of adverse responses to medications or any other problems associated with medications.[1]

Pharmacovigilance's scope and definition have changed to reflect the significance of a systemic approach to ensuring the safe use of medications. The specific objectives of pharmacovigilance are to promote public health and safety regarding the use of medications, as well as patient care and safety related to the use of medications and all other medical and paramedical treatments.[3]

To ensure that the anticipated benefits surpass the anticipated dangers, pharmacovigilance is involved in gathering information about a potential treatment to examine its advantages and hazards and devise ways to mitigate the discovered risks. The effectiveness of the connection between drug exposure and the occurrence of adverse reactions can be assessed using the ADR causality evaluation approach. Healthcare professionals make decisions regarding potential therapies for ADRs in patients by analyzing the cause informally. It comprises disclosure of information related to drug administration time, prior drug knowledge, dechallenge, and rechallenge[7]. The various pharmaceutical monitoring services are shown in the below figure.

Figure 1

ADVERSE DRUG REACTION

"A response to a medicine that is unpleasant and unanticipated, and that happens at levels typically employed in a man for the prevention, diagnosis, or treatment of disease, or for the alteration of physiological function." For marketed items, this term is widely recognized. ICH (International Centre on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use) guideline on Clinical Safety Data Management (E2A guidelines) further elaborates the definition of adverse drug reactions during the pre-approval (before marketing of the pharmaceutical product) phase. As per the ICH E2A guidelines:

All unpleasant and unanticipated reactions to a medicinal product connected to any dose should be regarded as adverse drug reactions in the preapproval clinical experience with a novel medicinal product or its new usages, particularly as the therapeutic dose(s) may not be identified.[4]

ADVERSE DRUG REACTION REPORTING

All healthcare professionals, including doctors, pharmacists, nurses, and other health specialists, are asked to provide clarification when an adverse drug reaction to a medicine is potentially dangerous or clinically significant. A negative drug reaction must be reported to pharmacovigilance.

SPONTANEOUS REPORTING SYSTEM

1. Regionalization

2. Repossession of further data

3. Access to all important pre and post-marketing information

4. Detailed drug utilization data.

5. Standardized Evaluation of causality and significance

6. Encouragement

Documentation of ADRs

The pharmacovigilance curriculum conveyed worldwide motivation that all suspected drug Related adverse events should be outlined. It takes interest in reports of the following:

(A) Every adverse effect suspected or occurred by new drugs and drugs of the current issue

(B) Documentation of various drugs that cause ADRs, which include death, life-threatening conditions, disability, hospitalization, and congenital abnormalities.

Any drug's substantial adverse reaction needs to be reported within seven days. Within eight days, the other information regarding adverse events should be disclosed.

Any pharmacovigilance center can provide the ADR form. The Center reviews the form before sending it to the regional Center, which then sends it on to the zonal center. Following a statistical review, the information is sent to the WHO-Uppsala Monitoring Committee (UMC).[13,14]

ADVERSE EVENTS REPORTING TIMELINES

All SAEs (severe adverse events) should be reported to the sponsor right once, unless they are specifically noted in the protocol or another document as not requiring immediate reporting, according to ICH E6.

The regulatory authorities should be notified of any fatal or unexpected ADRs that occur during clinical trials as soon as possible, but no later than seven calendar days after the sponsor becomes aware of the occurrence. An extensive report should then be submitted to the regulatory authorities within eight more calendar days. Serious unanticipated reactions (ADRs) that are not life-threatening or fatal must be reported as soon as practicable, but no later than 15 calendar days after the sponsor learns that the case fits the requirements for accelerated reporting.

After the clinical trial, adverse events are reported as part of the marketing application or in PSURs if they do not fit the criteria for expedited reporting.[15]

PROCEDURE FOR REPORTING ADRs

Any pharmacovigilance center's initial responsibility is to report any probable adverse drug reactions that are discovered. Information about ADRs needs to be tallied and reported.[14]

Elements in ADR reporting	Necessary information	others
What should be reported	Adverse reaction to drugs	Medication Overdose, ph detect
Who can report	Doctors, pharmacists, Nurses	All government And private Hospital staff
When it can be reported	Any adverse reaction if noticed	-
How to report	Through the filled yellow form	-
Where it can be reported	Complete filled ARD form should be Submitted to PVpI.	-

Monitoring of ADRs

ADR monitoring is the practice of continuously monitoring the undesirable effects caused by using any drug. Pharmacovigilance plays an imperative role in monitoring ADRs. Pharmaceutical regulators are required by law to monitor the market for their goods and keep track of any potential adverse reactions. The usage of numerous pharmaceutical goods, herbal medications, cosmetics, medical equipment, biology, etc. might result in ADRs. The goal of introducing this monitoring system is to ensure that patients receive healthy and helpful medications.

Negative and dangerous impacts of therapeutic products may occur if any adverse occurrences are not disclosed. Therefore, implementing ADR monitoring programs appropriately will aid in minimizing the negative effects of medicinal drugs.[11]

Benefits of ADR monitoring

An ADR monitoring and reporting program can furnish the following benefits:

1. It caters to information about the quality and safety of pharmaceutical products.

2. It initiates risk-management plans.

3. It prevents predictable adverse effects and helps in measuring ADR adherence.

4. It instructs the health care team i.e., patients, pharmacists, and nurses about adverse drug effects and creates awareness regarding ADRs. The main objective of ADR monitoring is to disclose the quality and frequency of ADRs and to identify the risk factors that can cause adverse reactions.[11]

Serious Adverse Event

A serious adverse event (SAE) in human drug trials is defined as any untoward a medical occurrence that is caused at any dose.

(a) Results in death

(b) Is life-threatening

(c) Require in-patient hospitalization

(d) Prolongation of existing hospitalization

(e) Causes congenital anomaly/birth defect.

These incidents must be reported by researchers in clinical study reports for human studies. According to research, publicly available accounts frequently fail to accurately describe these situations.[12,28]

MORBIDITY AND MORTALITY OF ADRs

One of the top 10 causes of illness and mortality in the industrialized world is adverse medication reactions. After heart disease and cancer, adverse medication reactions are the third biggest cause of mortality in the USA, claiming 100 000 to 218 000 lives per year. The severity of the issue might be overstated, though, as ADRs are frequently not detected, which results in underreporting. Adverse drug responses are a large contributor to hospital admissions, a considerable financial strain on healthcare, and are viewed as a serious public health issue. The cost of drug-related health issues in the ambulatory care environment in the USA was projected to be more than US$177 billion yearly. The estimated numbers for India would be 400,000 drug-related fatalities and 720,000 adverse events annually. Serious adverse drug reactions occur 6.7% of the time, while fatal adverse drug reactions occur 0.32 of the time.

Many medications will only have undergone short-term and selective effectiveness testing before licensure. Occasionally, 5000 people will receive the medicine before it is released, but in certain situations, as few as 500 wills. At least 30,000 patients must get the medicine to find an ADR that affects 1 in 10,000 patients. Due to the small number of participants in post-marketing clinical trials, it is difficult to accurately estimate a drug's ADR profile. Additionally, how the medicine is utilized in bigger populations is not at all comparable to the controlled setting of pre-marketing clinical trials. After release, when the medication is taken by more patients with a wider range of That usage restriction becomes clear. Due to a lack of long-term safety data, underrepresentation of demographics in clinical studies, and other factors a lack of knowledge about off-label usage. Additionally, the routine use of surrogate endpoints may provide inaccurate information on the effects of medications when compared to usage in actual patients. Additionally, previously unknown ADRs, some of which appear years after the distribution of medicine, may happen during the post-approval phase. The example that follows serves as an example of this. A significant but infrequent side effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors is

rhabdomyolysis. Rhabdomyolysis has, however, been linked to reports of the interaction between azithromycin and other statins.

Post-approval monitoring allows for the longer-term surveillance of the medication profile for unapproved purposes, co-morbidity effects, co-administrations, and the potential for non-compliance with drug administration guidelines.

One of the main aims of pharmacovigilance is signal detection. The WHO defines a signal as information that suggests there may be a link between a medicine and an adverse event, even if this link was previously unidentified or only partially recorded.

Depending on the severity of the incident and the accuracy of the information, typically more than one report is needed to create a signal. When signs are discovered, thorough investigations, including pharmacoepidemiological research and the necessary regulatory action, should be conducted.[30-44]

PHARMACOVIGILANCE IN 20 TH CENTURY: PRE AND POST THALIDOMIDE ERA

The famous pharmacologist Cloud Bernard once said, "Everything is dangerous, nothing is poisonous." This indicates that a drug's ability to behave as a medication or poison relies on its dosage. No medication is therefore harmful or safe. The dosage affects a drug's safety and effectiveness. There are still some historical occurrences that contributed to the development of pharmacovigilance. The two main occurrences among them are:

Sulfanilamide disaster: S.E. Massengill Company, U.S. was marketing sulfanilamide to treat Streptococcal infections such as tonsillitis and pharyngitis. There was a need for this medication in liquid form to make it more convenient for kids. It became a challenging undertaking because of the solubility issue. Sulfanilamide was later discovered to be soluble in diethylene glycol. Elixir sulfanilamide was created as a result and offered on the market.

Diethylene glycol started to have harmful effects over time, and 107 fatalities were documented. As a result, the need for pharmaceutical safety. The Food, Drug, and Cosmetic Act of 1938 was enacted by the American government. The problem with this regulation was that it focused on medication safety rather than medicinal effectiveness. Under this law, only the drug's safety, not its effectiveness, was being demonstrated.[2,9]



Figure 2: Image of elixir sulfanilamide (1937)

Thalidomide Tragedy: Thalidomide, a sedative medicine, was first made available in 1950 by the German business West Pharmaceuticals. It helps people fall asleep naturally and wake up without a hangover. The medication gained popularity, and additional research on animals using thalidomide showed that no amount of thalidomide may cause an animal's death. As a result, the corporation promoted Thalidomide as the safest medicine and convinced people to buy it by telling them that suicide was impossible while taking it.

It was helpful for pregnant ladies with morning sickness since it is a sedative. Therefore, West Pharmaceuticals advertised the medicine to expectant mothers. The incidence of phocomelia, a condition in which a newborn's upper and lower limbs are short, sharply increased in November 1961. It turned into a major problem to be addressed at that time.



Malformations due to maternal ingestion of thalidomide (Schardein 1982 and Moore 1993).

Meanwhile, an Australian obstetrician, Dr. William McBride, and a German pediatrician, Dr. Widukin Lenz came up with some data and said that the drug Thalidomide was causing phocomelia. After this, subsequently, animal trials were conducted, and proven that the drug, which was the safest, became the reason for serious congenital anomalies.



THALIDOMIDE AND CONGENITAL ABNORMALITIES

SIR,—Congenital abnormalities are present in approximately 1·5% of babies. In recent months I have observed that the incidence of multiple severe abnormalities in babies delivered of women who were given the drug thalidomide (' Distaval ') during pregnancy, as an antiemetic or as a sedative, to be almost 20%.

These abnormalities are present in structures developed from mesenchyme—i.e., the bones and musculature of the gut. Bony development seems to be affected in a very striking manner, resulting in polydactyly, syndactyly, and failure of development of long bones (abnormally short femora and radii).

Have any of your readers seen similar abnormalities in babies delivered of women who have taken this drug during pregnancy?

Hurstville, New South Wales. W. G. MCBRIDE.

Figure 3: McBride letter to Lancet- June 1961

Because of these adverse medication reactions, the government was forced to pass legislation mandating that drugs be tested on both people and animals before being approved for use. The licensing authority of India is responsible for identifying and preventing adverse drug reactions.

The marketing firm is required to provide ADR with information on the new medicine by DCGI CDSCO. Early drug development clinical studies were carried out in the USA. Later, the Indian government began to carry out its clinical trials, making pharmacovigilance a crucial component in Indian drug development.[2,10]

PHARMACOVIGILANCE IN INDIA AND THE CURRENT SYSTEM

India has 15,000 hospitals with a bed capacity of 6,24,000 and more than 500,000 competent physicians. It is the world's fourth-largest pharmaceutical manufacturer. It is becoming a significant trial center worldwide. In our nation, several new pharmaceuticals are introduced. To safeguard the populace from any possible harm that any of these new pharmaceuticals may cause, the nation needs a robust pharmacovigilance system. The National Pharmacovigilance Program has been launched by the Central Drugs Standard Control Organization (CDSCO), which is fully aware of the scope of the work at hand. The WHO publication "Safety Monitoring of Medicinal Products- Guidelines for Setting Up and

Running Pharmacovigilance Center" serves as the foundation for most of its recommendations.

The specific aims of pharmacovigilance programmers are to:

- Contribute to the regulatory assessment of benefit, harm, and effectiveness, encouraging their safe, rational, and effective use (including cost-effective use).
- Improve patient care about the use of medicine and all medical and Paramedical interventions.
- Improve public health and safety regarding the use of medicines.
- Promote understanding, education, and clinical training in pharmacovigilance and its effective communication to the public.[14]

Current Status:

There are more than 6,000 licensed pharmaceutical producers and more than 60,000 branded formulations in the sizable nation of India. India is the fourth-largest pharmaceutical manufacturer in the world and is developing into a center for clinical research trials. The interval between a drug's approval for sale and its availability in India, however, has been shortened to the point that longer-term safety data are no longer accessible. Additionally, Indian pharmaceutical businesses have enhanced their capacity to create and market new medications through their research initiatives, underscoring the need of setting up respectable internal pharmacovigilance standards to identify adverse drug occurrences. Earlier, the Drug Technical Advisory Board (DTAB) had suggested that pharmaceutical firms be compelled to disclose the side effects of sold medications.

Despite the proposals' proactivity, the mandate law was also founded in March of 2116. Since many pharmaceutical firms consider reporting ADRs to be standard business practice, PvPI and its stakeholders have made progress in getting ADR reports through regular interactions and participatory dialogues. As a result, the ADR reporting rate for the pharmaceutical industry to PvPI in 2015 was 18.80%. On April 15, 2011, the NCC was transferred from the AIIMS in New Delhi to the Indian Pharmacopoeia Commission in Ghaziabad, Uttar Pradesh, to support the more effective execution of the program. The primary objective of the NCC at IPC is to produce impartial data on medication safety that is like global drug safety monitoring standards.

Good Pharmacovigilance Practices (GPPs) and applicable legislation compel pharmaceutical businesses to regularly evaluate the advantages and dangers of their products. The NCC-PvPI actively participates in providing training to seasoned pharmacovigilance professionals on the foundations and regulatory elements of pharmacovigilance, as well as to young pharmacy, medical, and paramedical professionals, during the year. On October 30th, 2017, the WHO designated the NCC-PvPI IPC in Ghaziabad as a Collaborating Center for Pharmacovigilance in Public Health Programs and Regulatory Services. The PvPlin 2015 created the Materiovigilance Programme (MvPI) of India to assess adverse incidents linked to medical devices in India. Members of the MvPI recently met at the IPC in May 2017 to talk about methods for gauging the effectiveness of the ambitious initiative. The conclusion was that experienced biomedical engineers would be hired, and PvPI would provide them with the necessary training.[5]



History of Pharmacovigilance

Year	Developments
1937	Death of more than 100 children due to toxicity of sulfanilamide.
1950	Aplastic anaemia reported due to chloramphenicol toxicity.
1961	Worldwide tragedy due to thalidomide toxicity.
1963	16th world health congregation recognize significant to rapid action on ADR's.
1968	WHO research project for international drug monitoring on pilot scale.
1996	Global standards level clinical trials initiated in India.
1997	India attached with WHO ADR's monitoring program.
1998	Initiation of pharmacovigilance in India.
2002	67th National Pharmacovigilance Center established in India.
2004-05	India launched National Pharmacovigilance Program.
2009-10	PvPI started.

Figure 4: Development of Pharmacovigilance

FUTURE OUTLOOK

Future public health protection will require a robust pharmacovigilance system that can identify emerging ADRs and put regulatory measures in place. There hasn't been much focus on the development of data that can help a doctor or a patient to decide. The main goal of pharmacovigilance is to gather and disseminate these data. Information on the safety of drug active surveillance is essential. In addition to more conventional groups like health professionals, PV will need to concentrate on patients in the future as a source of information. The DCGI should move quickly to improve PV by integrating Good Pharmacovigilance Practice (GPP) into processes and procedures to improve regulatory compliance, clinical trial safety, and post-marketing surveillance.

A reliable PV system is necessary for the safe usage of medications. It will be advantageous to consumers, pharmaceutical companies, regulatory agencies, and healthcare professionals. Due to the abundance of clinical studies and other clinical research Understanding the importance of pharmacovigilance and how it affects the life cycle of a product is crucial for operations taking place in India. DCGI has worked hard to develop a pharmacovigilance system that is dependable and efficient. But more effort and strategic planning are necessary to fulfill population growth expectations and make sure that all data is captured and processed. DCGI may go one step further and contract private companies to provide instruction to solve the challenges of inexperience and a lack of skilled staff and set up an effective pharmacovigilance system.

After considering the issues and obstacles that India has in developing an effective.

pharmacovigilance system, the following suggestions may be made:

- Established and maintained an effective pharmacovigilance system.
- Introducing PV inspections and making its reporting mandatory.
- Discussions at a high level with a variety of stakeholders.
- Expand the number of trained scientific and medical assessors in the Drug

Control General of India office for PV.

- Creating a single adverse event reporting form that can be used by everyone in

any country.

 A Clinical trial and post-marketing database for SAEs/SUSARs and ADRs are being built for signal detection and access to relevant data from different stakeholders.

 Keep track of all new medications and indications in a standard database for each pharmaceutical company.

 Medical students, pharmacists, and nurses receive pharmacovigilance education and training.

 Collaborating with pharmacovigilance groups to improve medication safety as information technology advances, new potential for national and worldwide collaborations to improve post-marketing surveillance programs and improved drug safety has emerged.

 In India, establishing a network of pharmacovigilance and Pharmacoepidemiologists.[5]

HISTORICAL PERSPECTIVE OF WHO-DRUG SAFETY MONITORING

In 2002, there were pharmacovigilance facilities in over 65 nations.

The WHO coordinates who joins the WHO for International Drug Monitoring.

Uppsala Monitoring Center or Collaborating Centre for International Drug Monitoring (UMC). Pharmacovigilance today has a solid scientific foundation and is essential to efficient clinical practice. The discipline must increase its standards and requirements for contemporary public health. The WHO Pilot Research Project for International Drug Monitoring was established because of a resolution (WHA 16.36) issued by the sixteenth World Health Assembly that reiterated the necessity for quick action regarding the sharing of information on adverse drug reactions. The goal of this was to create a system that could be used globally for detecting previously undiscovered or poorly understood harmful effects of medicines[17,18].

WORLDWIDE SOLDIERS OF PHARMACOVIGILANCE

The process of medication safety monitoring involves a variety of partners in a complicated and crucial interaction. The wants and expectations of the public, healthcare providers, and other stakeholders must be collaboratively anticipated, understood, and addressed by these partners, Politicians, policymakers, administrative personnel, and health specialists.

Quality Assurance and Safety: The group is a member of the WHO Health Technology and Pharmaceuticals cluster's Department of Essential Drugs and Medicines Policy. The department's mission is to close the enormous gap between the promise that life-saving medications have and the widespread lack of accessibility to, affordability of, the safety of, and correct use of medications among millions of people, particularly the underprivileged and impoverished.[19]

Uppsala Monitoring Centre: The main responsibility of the Uppsala Monitoring Centre is to oversee the global database of ADR reports that are received from National Centers.

To encourage quick signal detection, the UMC created consistent reporting by all National Centers and eased communication between nations.

National Pharmacovigilance Centers: The public's understanding of medication safety has significantly grown thanks in large part to the work of National Centers. This change is partially explained by the fact that many national and regional centers are in healthcare facilities such as hospitals, medical colleges, or poison and drug information centers rather than behind the walls of a drug-regulating body. Large cities in wealthy nations have prescription event monitoring systems (PEM) and record linking to create active surveillance programs to gather epidemiological data adverse to certain medications. The United States of America and New Zealand both have such systems in place. The total cost of a pharmacovigilance system is incredibly low when compared to the national spending on medications or the cost of ADRs to the country.[20,21,22]

Hospitals and Universities: Several healthcare facilities have implemented careful monitoring programs for drug errors and bad reactions in their clinics, wards, and emergency rooms. To assess the damage connected with medications after they have been marketed, case-control studies and other pharmacoepidemiological techniques are being employed more often. Teaching, training, research, policy formulation, clinical research, ethical committees (institutional review boards), and the clinical services offered by academic institutions of pharmacology and pharmacy have all contributed significantly to society.[23-25]

Health Professional: Initially, doctors were the only professionals requested to report using the skill of differential diagnosis to determine if a certain symptom is caused by a disease or medication. Different sorts of healthcare providers may see various drug-related issues today.[26,27]

Patients: Only a patient is aware of the true benefits and risks associated with a medication. The pharmacovigilance system will operate more effectively with direct patient involvement and make up for some of the drawbacks of systems that rely only on reports from medical experts.[16]

RISK MANAGEMENT IN PHARMACOVIGILANCE

Risk management in pharmacovigilance is undertaken to promote the safe use of medicines and safeguard the health of patients. It is a set of activities performed for the identification of risk, risk assessment, and risk minimization and prevention. Risk management has the following stages:

 Identification and characterization of the safety profile of the medicinal product

 Planning of pharmacovigilance activities to characterize risks and identify new risks

 Planning and implementation of risk minimization and mitigation and assessment of the effectiveness of these activities

 Document post-approval obligation that has been imposed as a condition of the marketing authorization. All these activities together constitute the risk management plan, which is required to be submitted during the authorization of the drug. Consequences of finding a significant safety issue may include any of the following activities:

 Amending the protocol

 Temporarily suspending enrollment

 Discontinuing the study

 Discontinuing the development of the medicinal product

 Implementing a development risk management plan (RMP) or risk evaluation

and mitigation strategy (REMS).

The apex of the pharmacovigilance activity pyramid is risk management. The processing and examination of individual adverse events and other safety data, the review and assessment of aggregated data, and other related efforts have culminated in these tasks.

Risk Management Plans and Risk Evaluation and Mitigation Strategies

The ICH E2E (Pharmacovigilance Planning) was first developed to ensure uniformity and harmonization, particularly during the early post-marketing period of medical goods. The RMP (EU) and the REMS (USA) are now typical components of pharmacovigilance planning. The regulatory organizations in the US and Europe have improved their recommendations on benefit-risk assessment and mitigation during the last few years.



Figure 5: Pharmacovigilance activity pyramid

Both the RMP and the REMS are meant to reduce potential hazards associated with a pharmaceutical product through actions and to communicate those potential dangers to patients and healthcare professionals. A thorough communication strategy concerning safety problems, and particular components to ensure the safe use of a product, such as necessary laboratory tests or prescriber training, an implementation plan and a deadline for evaluation are just a few examples of parts.

The RMP or REMS may currently be developed at any point during clinical development, however, they are often presented as a part of the marketing application. Within the EU, a

regularly required comprehensive description of the pharmacovigilance system is RMPs. If there is cause to believe that a plan could be required in the USA, based on non-clinical evidence, early usage data, class data for the medicinal drug, or other considerations, the regulatory authorities may request one.

Regulatory agencies may ask for a REMS or an updated RMP if new safety information becomes available subsequently. The strategy may also contain extra pharmacovigilance measures like active surveillance, additional clinical or epidemiological trials, specialist training, or limited access. The actions taken must be sufficient to reduce the risk of damage such that benefits still outweigh risks, and to guarantee that the risk reduction processes are communicated and executed.[16]

SUMMARY CONCLUSIONS:

ADRs have recently been identified as the primary cause of the 10% global death and morbidity rate. When detrimental effects and toxicity do manifest, particularly when they were previously unrecognized, they must be recorded, examined, and their significance adequately conveyed to the audience capable of understanding the material.

Pharmacovigilance has grown to be a crucial component of drug control. Although it is far from an ideal system, spontaneous monitoring will probably continue to be the norm in underdeveloped countries for the foreseeable future. The only method to ensure that a medicine is safe over its entire life cycle is through pharmacovigilance. It is extremely important since clinical studies often struggle to find unusual and extremely rare ADRs.

We can make the world a safer place than it is today if all medical practitioners view ADR reporting as an ethical need and a substantial duty. After the notion evolved, there were considerable effects on pharmacovigilance to make it more functional, and day by day, we are approaching the goal. We must make sure the pharmacovigilance system is effective.

REFERENCES

1. JE Campbell, M Gossell-Williams, MG Lee, A Reviewof Pharmacovigilance, 2013
2. Garima Dhingra, Sonia Tanwar, Devender Sharma, Shweta Parihar, A Review of Pharmacovigilance. Journal of Pharmacovigilance and Drug Research 2022.
3. Olsson, S., & Harrison-Woolrych, M. (2018). The role and strategy of ISoP in global pharmacovigilance. International journal of clinical pharmacy, 40(4), 740–743.
4. S.K. Gupta (2018). Textbook of Pharmacovigilance, chapter 5: Adverse drug reactions; classification, mechanism, and interaction.

5. Kajal pansare, Ganesh sonawane(2021). History, current status and future aspects of pharmacovigilance in india.
6. Beninger P. (2018). Pharmacovigilance: An Overview. Clinical therapeutics, 40(12), 1991–2004.
7. Almandil N. B. (2016). Healthcare professionals' awareness and knowledge of adverse drug reactions and pharmacovigilance. Saudi medical journal, 37(12), 1359–1364.
8. Martin, L. G., Hanssens, Y., &Paudyal, V. (2018). Overview of this issue: pharmacovigilance, what is new? International journal of clinical pharmacy, 40(4), 737–739.
9. Montané, E., &Santesmases, J. (2020). Adverse drug reactions. Reaccionesadversas a medicamentos. Medicinaclinica, 154(5), 178–184.
10. Dylan Fernandes, S., Anoop, N. V., Castelino, L. J., & Narayana Charyulu, R. (2019). A national approach to pharmacovigilance: The case of India as a growing hub of global clinical trials. Research in social & administrative pharmacy: RSAP, 15(1), 109–113.
11. Moore N (2001). The role of clinical pharmacologist in management of ADRs. Drugsafety, 211(1): 1-7.
12. The importance of pharmacovigilance; safety monitoring of medical products, Geneva, WHO, 2002.
13. Hall et al. 1995; Horbuckle et al. 1999; Tuntti and Neuroren 2002.
14. Lakshmi Anusha, M. Aashritha, K. Teja and R. Sridhar:A Review on Pharmacovigilance and its importance; World journal of pharmacy and pharmaceutical sciences: vol 6 issue 1, 300-310.
15. Suzanne Gagnon, Peter Schueler, James Fan; Chapter13 Pharmacovigilance and risk management; Global Clinical Trials Playbook,146,157,158,2012.
16. Jeetu G, Anusha G- Pharmacovigilance: a Worldwide master key for drug safety monitoring.
17. whqlibdoc.who.int [homepage on the Internet]. Geneva: World Health Organization. 1973. Handbook of resolutions and decisions of the World Health Assembly and Executive Board. Available from: http://whqlibdoc.who.int/wha_eb_handbooks/9241652063_Vol2.pdf [Last cited on 2009 Dec 26]
18. Lared NL. Pharmacists' role in reporting adverse drug reactions in an international perspective. 2003. Available from: http://www.lareb.nl/documents/pds2004_1291.pdf [last cited on 2010 Jan 28] [PubMed]
19. . WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy 2000-2003. Available from: http://www.apps.who.int/medicinedocs/en/d/Jwhozip16e/8.html [last cited on 2010 Jan 10]
20. Olsson S. The role of the WHO Programme for International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998; 19:1–10. [PubMed] [Google Scholar]
21. Coulter DM. The New Zealand intensive medicines monitoring programme in proactive safety surveillance. Pharmacoepidemiol Drug Saf. 2000; 9:273–80. [PubMed] [Google Scholar]
22. Mackay FJ. Post-marketing studies: The work of the drug safety research unit. Drug Saf. 1998; 19:343–53. [PubMed] [Google Scholar]
23. Folb PI, ten Ham M. Drug monitoring in developing countries: A drug regulator's perspective. Drug Inf J. 1995; 29:303–5. [Google Scholar]
24. Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol. 1998; 45:427–31. [PMC free article] [PubMed] [Google Scholar]
25. Moore N. The role of the clinical pharmacologist in the management of ADRs. Drug Saf. 2001; 24:1–7. [PubMed] [Google Scholar]
26. Hall M, McCormack P, Arthurs N, Feely J. The spontaneous reporting of ADRs by nurses. Br J Clin Pharmacol. 1995; 40:173–5. [PMC free article] [PubMed] [Google Scholar]
27. Hornbuckle K, Wu HH, Fung MC. Evaluation of spontaneous adverse event reports by primary reporter: A 15-year review (1983 to 1997) Drug Inf J. 1999;33:1117–24. [Google Scholar]
28. J.P Loannidis, J Lau. Completeness of safety reporting in randomized trials: an evaluation of seven medical areas. JAMA, 2001; 285(4): 437-443.
29. Edwards IR, Aronson JK, Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-59.
30. Lazarou J, Pomeranz BH, Corey P, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279;1200-5
31. Pillans PI. Clinical perspectives in drug safety and adverse drug reactions. Expert Rev Clin Pharmacol [serial on the internet] 2008; 1: 695-705. Doi: 10.1586/17512433.1.5.695.

32. Aspinall MB, Whittle J, Aspinall SL, Maher RL Jr, Good CB. Improving adverse drug reaction reporting in ambulatory care clinics at a Veterans Affairs hospital. Amer J Health Syst Pharm 2002;59: 841-5
33. Ernst FR, Grizzle AJ. Drug related morbidity and mortality: updating the cost of illness model. J Am Pharm Assoc (Wash) 2001; 59: 841-5.
34. White TJ, Arakelian A, Rho JP. Counting the costs of drug related adverse event. Pharmacoeconomics 1999; 15: 445-58.
35. Benkirane R, Pariente A, Achour S, Ouammi L, Azzouzi A, Soulaymani R. Prevalence, and preventability of adverse drug events in a teaching hospital: a cross sectional study. East mediterr health.2009; 15:1145-1155.
36. Jones J. Adverse drug reactions in the community health setting: approaches to recognizing, counselling, and reporting. Fam Community health 1982; 5:58-67.
37. Brvar M, Fokter N, Bunc M, Mozina M. The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty. *BMC Clin Pharmacol.* 2009; 9:8–8. doi: 10.1186/1472-6904-9-8.
38. Carmago AL, Cardoso Ferreira MB, Heineck I. Adverse drug reactions: a cohort study in internal medicine units at a university hospital. *Eur J Clin Pharmacol.* 2006; 62:143–149.
39. Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. *BMC Clin Pharmacol.* 2007; 7:8–8.
40. Zolezzi M, Parsotam N. Adverse drug reaction reporting in New Zealand: implications for pharmacists. *Ther Clin Risk Manag.* 2005; 1:181–188.
41. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention
42. Finklestein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer- and service-specific estimates. Health Aff (Millwood) 2009;28: w822–w831. doi: 10.1377/hlthaff.28.5. w822. Epub 2009 Jul 27.
43. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics–2010 update. Circulation. 2010; 121:948–954.
44. Hochberg AM, Reisinger SJ, Perason RK, O'Hara DJ, Hall Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions. Arch Intern Med. 2005; 165:1363–1369.
45. World Health Organization. WHO Policy Perspectives on Medicines. Geneva: World Health Organization; 2004. Pharmacovigilance: ensuring the safe use of medicines.
46. . Stafford RS. Regulating off-label drug use: rethinking the role of the FDA. N Engl J Med. 2008; 358:1427–1429.
47. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Inter Med. 1996; 125:605–613.
48. Ray WA, Stein CM. Reform of drug regulation – beyond an independent drug-safety board. N Engl J Med. 2006; 354:194–201.
49. Pirmohamed M, Breckenridge A, Kitteringham NR, Park B. Adverse drug reactions. Br Med J. 1998; 316:1295–1298.
50. Strandell J, Bate A, Hägg S, Edwards IR. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol. 2009; 68:427–434.
51. Egberts TCG. Signal detection: historical background. Drug Saf. 2007; 30:607–609.
52. Hauben M, Reich L. Communication of findings in pharmacovigilance: use of the term "signal" and the need for precision in its use. Eur J Clin Pharmacol. 2005; 61:479–480.
53. Edwards IR, Biriell C. Harmonisation of pharmacovigilance. Drug Saf. 1994; 10:93–102.
54. Stahl M, Edwards IR, Bowring G, Kiuru A, Lindquist M. Assessing the impact of drug safety signals from the WHO database presented in 'SIGNAL': results from a questionnaire of national pharmacovigilance centers. Drug Saf. 2003; 26:721–727.
55. Hochberg AM, Reisinger SJ, Perason RK, O'Hara DJ, Hall K. Using data mining to predict safety actions from FDA adverse event reporting system data. Drug Inf J. 2007; 41:633–643.